151 related articles for article (PubMed ID: 28099210)
81. The necessity for rigour in rare disease study design.
Baker LH
Lancet Oncol; 2019 Sep; 20(9):1190-1192. PubMed ID: 31331700
[No Abstract] [Full Text] [Related]
82. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
Toulmonde M; Pulido M; Ray-Coquard I; Andre T; Isambert N; Chevreau C; Penel N; Bompas E; Saada E; Bertucci F; Lebbe C; Le Cesne A; Soulie P; Piperno-Neumann S; Sweet S; Cecchi F; Hembrough T; Bellera C; Kind M; Crombe A; Lucchesi C; Le Loarer F; Blay JY; Italiano A
Lancet Oncol; 2019 Sep; 20(9):1263-1272. PubMed ID: 31331699
[TBL] [Abstract][Full Text] [Related]
83. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
84. Favorable clinical efficacy of cytotoxic chemotherapy in patients with progressive desmoid tumors: a retrospective real-world study.
Oh CR; Jeong H; Kim W; Lee JS; Song SY; Song JS; Cho KJ; Chung HW; Lee MH; Hong JY; Lee J; Kim JE; Ahn JH
Int J Clin Oncol; 2024 Jun; 29(6):853-861. PubMed ID: 38526622
[TBL] [Abstract][Full Text] [Related]
85. Current therapies and future prospective for locally aggressive mesenchymal tumors.
Maleddu A; Zhu J; Clay MR; Wilky BA
Front Oncol; 2023; 13():1160239. PubMed ID: 37546427
[TBL] [Abstract][Full Text] [Related]
86. Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma.
Alshamsan B; Badran A; Alshibany A; Maraiki F; Elshenawy MA; Elhassan T; Atallah JP
Cancer Manag Res; 2021; 13():6755-6766. PubMed ID: 34512015
[TBL] [Abstract][Full Text] [Related]
87. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
88. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
89. The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution.
Zheng C; Zhou Y; Wang Y; Luo Y; Tu C; Min L
Drug Des Devel Ther; 2020; 14():3941-3950. PubMed ID: 33061299
[TBL] [Abstract][Full Text] [Related]
90. Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review.
Timbergen MJM; Smits R; Grünhagen DJ; Verhoef C; Sleijfer S; Wiemer EAC
Front Oncol; 2019; 9():397. PubMed ID: 31165043
[TBL] [Abstract][Full Text] [Related]
91. Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects.
Wang Z; Wu J; Tian X; Hao C
Front Med; 2019 Aug; 13(4):427-437. PubMed ID: 30798508
[TBL] [Abstract][Full Text] [Related]
92. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care?
Husson O; Younger E; Dunlop A; Dean L; Strauss DC; Benson C; Hayes AJ; Miah A; van Houdt W; Zaidi S; Smith M; Williams J; Jones RL; van der Graaf WTA
Support Care Cancer; 2019 Mar; 27(3):965-980. PubMed ID: 30155568
[TBL] [Abstract][Full Text] [Related]
93. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Libertini M; Mitra I; van der Graaf WTA; Miah AB; Judson I; Jones RL; Thomas K; Moskovic E; Szucs Z; Benson C; Messiou C
Clin Sarcoma Res; 2018; 8():13. PubMed ID: 29785261
[TBL] [Abstract][Full Text] [Related]
94. Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.
Li S; Fan Z; Fang Z; Liu J; Bai C; Xue R; Zhang L; Gao T
Chin J Cancer Res; 2017 Oct; 29(5):455-462. PubMed ID: 29142465
[TBL] [Abstract][Full Text] [Related]
95. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Kasper B; Baumgarten C; Garcia J; Bonvalot S; Haas R; Haller F; Hohenberger P; Penel N; Messiou C; van der Graaf WT; Gronchi A;
Ann Oncol; 2017 Oct; 28(10):2399-2408. PubMed ID: 28961825
[TBL] [Abstract][Full Text] [Related]
96. Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs Z; Messiou C; Wong HH; Hatcher H; Miah A; Zaidi S; van der Graaf WT; Judson I; Jones RL; Benson C
Anticancer Drugs; 2017 Apr; 28(4):421-426. PubMed ID: 28099210
[TBL] [Abstract][Full Text] [Related]
97. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
[TBL] [Abstract][Full Text] [Related]
98. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study.
Noujaim J; Gupta AA; Holloway CL; Saleh R; Srikanthan A; Lemieux C; Soroka HP; Tibout P; Turcotte R; Feng X; Abdul Razak AR; Costa P
Eur J Cancer; 2024 Jul; 205():114119. PubMed ID: 38759389
[TBL] [Abstract][Full Text] [Related]
99. Pazopanib does not bring remarkable improvement in patients with angiosarcoma.
Kitamura S; Yanagi T; Inamura Y; Hata H; Imafuku K; Yoshino K; Shimizu H
J Dermatol; 2017 Jan; 44(1):64-67. PubMed ID: 27569550
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
